RT Journal Article
SR Electronic
T1 97 Primary malignant vaginal melanoma: single institution’s experience of 52 cases
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A50
OP A50
DO 10.1136/ijgc-2019-IGCS.97
VO 29
IS Suppl 3
A1 N Phoolcharoen
A1 M Frumovitz
A1 A Jazaeri
A1 GB Chrisholm
A1 M Onstad
YR 2019
UL http://ijgc.bmj.com/content/29/Suppl_3/A50.1.abstract
AB Objectives To assess clinical and pathologic features that impact outcome in patients with vaginal melanoma.Methods This is a retrospective review of vaginal melanoma cases treated at single institution between 1990 – 2015. Clinical and pathological characteristics were reviewed. Progression-free survival (PFS) and overall survival (OS) were calculated from the first treatment date.Results Fifty-two patients with median age of 60.5 years (32.0–86.0) were identified. Using the AJCC clinical staging, 11.5% were stage I, 61.6% were stage II, 19.2% were stage III and 7.7% were stage IV. The median tumor size was 3.0 cm with median tumor thickness 8.0 mm. 81% experienced disease recurrence with 40.5% local recurrence, 23.8% distant recurrence and 35.7% both. Overall, the median PFS was 8.9 months with a 5-year PFS of 16%. The OS was 19.8 months with a 5-year OS of 18%. 44 patients underwent surgery as part of their primary therapy while 8 women did not have surgery. Patients who underwent surgery had a median OS 20.7 VS 9.3 months for those who did not (p<0.01). Patients who were diagnosed as stage I-II had significantly longer survival than patients who were stage III-IV (median OS 24.4 VS 13.4 months, p=0.03). In addition, patients who underwent pelvic exenteration had significantly longer survival (median OS 28.9 VS 17.2 months, p=0.02).Conclusions Vaginal melanoma most commonly presents at an early stage but is still associated with poor outcomes. Patients who have localized disease, who are able to undergo primary surgical treatment and who undergo pelvic exenteration have longer OS.